Caissa Capital Management ltd.
SEC CIK 1929354 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| AVTX | Avalo Therapeutics, Inc. | 10% | 0 | -$375.0K | — | 15 | 2023-04-10 | 2023-06-26 |
Most active insiders at AVTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Sullivan Christopher Ryan | CFO | — | $3.72M |
| 2 | Doyle Mittie | Chief Medical Off | — | $2.98M |
| 3 | VARKI PAUL | CLO | — | $1.51M |
| 4 | Goldman Jonathan | Dir | — | $163.0K |
| 5 | Chan Mitchell | Dir | — | $72.5K |
| 6 | Riley Jennifer | Chief Strategy Off | — | $52.0K |
| 7 | Truex Samantha | Dir | — | — |
| 8 | KANTOFF AARON | Dir | — | — |
| 9 | NEIL GARRY ARTHUR | CEO, Dir | — | — |
| 10 | KAPLAN GILLA | Dir | — | — |
Caissa Capital Management ltd. made no open-market trades at AVTX in the last 12 months.
Transactions 15
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-06-27 | 2023-06-26 | AVTX | Avalo Therapeutics, Inc. | Caissa Capital Management ltd. | 10% | P - Purchase | $0.64 | -1.43M | 0 | -100% | -$912.4K |
| 2023-06-27 | 2023-06-26 | AVTX | Avalo Therapeutics, Inc. | Caissa Capital Management ltd. | 10% | P - Purchase | $0.62 | -182.3K | 0 | -100% | -$113.0K | |
| MI | 2023-06-20 | 2023-06-15+ | AVTX | Avalo Therapeutics, Inc. | Caissa Capital Management ltd. | 10% | P - Purchase | $3.87 | +8,160 | 1.43M | +0.6% | +$31.6K |
| MI | 2023-06-14 | 2023-06-12+ | AVTX | Avalo Therapeutics, Inc. | Caissa Capital Management ltd. | 10% | P - Purchase | $3.77 | +16.9K | 1.41M | +1% | +$63.6K |
| MI | 2023-06-09 | 2023-06-07+ | AVTX | Avalo Therapeutics, Inc. | Caissa Capital Management ltd. | 10% | P - Purchase | $3.91 | +14.4K | 1.40M | +1% | +$56.4K |
| I | 2023-06-02 | 2023-05-31 | AVTX | Avalo Therapeutics, Inc. | Caissa Capital Management ltd. | 10% | P - Purchase | $2.87 | +844 | 1.39M | +0.1% | +$2,422 |
| MI | 2023-05-30 | 2023-05-25+ | AVTX | Avalo Therapeutics, Inc. | Caissa Capital Management ltd. | 10% | P - Purchase | $2.80 | +2,671 | 1.39M | +0.2% | +$7,466 |
| MI | 2023-05-24 | 2023-05-24 | AVTX | Avalo Therapeutics, Inc. | Caissa Capital Management ltd. | 10% | P - Purchase | $2.98 | +9,000 | 1.38M | +0.7% | +$26.8K |
| MI | 2023-05-22 | 2023-05-18+ | AVTX | Avalo Therapeutics, Inc. | Caissa Capital Management ltd. | 10% | P - Purchase | $3.36 | +26.6K | 1.37M | +2% | +$89.4K |
| MI | 2023-05-16 | 2023-05-12+ | AVTX | Avalo Therapeutics, Inc. | Caissa Capital Management ltd. | 10% | P - Purchase | $2.52 | +4,379 | 1.35M | +0.3% | +$11.0K |
| MI | 2023-05-08 | 2023-05-04+ | AVTX | Avalo Therapeutics, Inc. | Caissa Capital Management ltd. | 10% | P - Purchase | $2.77 | +25.0K | 1.34M | +2% | +$69.3K |
| MI | 2023-04-27 | 2023-04-25+ | AVTX | Avalo Therapeutics, Inc. | Caissa Capital Management ltd. | 10% | P - Purchase | $2.99 | +7,500 | 1.32M | +0.6% | +$22.4K |
| MI | 2023-04-24 | 2023-04-20+ | AVTX | Avalo Therapeutics, Inc. | Caissa Capital Management ltd. | 10% | P - Purchase | $3.07 | +17.5K | 1.31M | +1% | +$53.6K |
| MI | 2023-04-18 | 2023-04-17+ | AVTX | Avalo Therapeutics, Inc. | Caissa Capital Management ltd. | 10% | P - Purchase | $2.95 | +25.0K | 1.29M | +2% | +$73.8K |
| MI | 2023-04-11 | 2023-04-10+ | AVTX | Avalo Therapeutics, Inc. | Caissa Capital Management ltd. | 10% | P - Purchase | $2.53 | +56.3K | 1.24M | +5% | +$142.4K |
Purchase Sale Sale after option exercise All abbreviations